Get started
Work

Duchenne muscular dystrophy

Year: 2021
Type: review
DOI: 10.1038/s41572-021-00248-3
Institutions: University of Missouri, Universitair Ziekenhuis Leuven, National Center of Neurology and Psychiatry, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Centro Clinico Nemo, Leiden University Medical Center
Language: English
Open Access status: bronze
Funders: Pfizer, Parent Project Muscular Dystrophy, University of Missouri, Duchenne Research Fund, Taiho Pharmaceutical, PTC Therapeutics, Sarepta Therapeutics, Nippon Shinyaku, Prinses Beatrix Spierfonds, Astellas Pharma, Leids Universitair Medisch Centrum, Duchenne Parent Project, ProQR Therapeutics, Italfarmaco, Silence Therapeutics, National Institutes of Health, Noguchi Memorial Institute for Medical Research, University of Ghana, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Awards: G2537392460, Treatment of Duchenne Muscular Dystrophy with the Muscle Calcium Pump, G6260706663, CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy, G9000017359, G9000088493
OpenAlex ID: W3131782536
FWCI: 17.08
Cites: 292
Cited by: 1,315
Related to: 10